For US residents only

Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] logo
Sign up now
Boy with backpack in school (patient portrayal)

Taking ALPROLIX®

Boy with backpack in school (patient portrayal)

Taking ALPROLIX®

ALPROLIX prophy offers flexible dosing options to keep pace with your lifestyle

Convenient starting doses:

todo

Adults and adolescents 12 years of age and older

  • 50 IU/kg once weekly
  • 100 IU/kg every 10 days
  • Dosing schedule may be adjusted based on individual response
todo

Kids up to 11 years of age
 

  • 60 IU/kg once weekly
  • Dosing schedule may be adjusted based on individual response
  • More frequent or higher doses may be needed, especially in kids under 6 years old

ALPROLIX offers 6 different vial sizes—which may help you achieve single-vial infusions

6 different vial illustrating vial-strength options
Graphic not representative of actual drug product vials.
Man with vest outdoors (patient portrayal)
Frequently asked questions
Get answers to commonly asked questions about ALPROLIX.
 
Read the FAQs
Alex is a real patient who switched to ALPROLIX
Patient stories
See how real ALPROLIX patients 
manage hemophilia B.
Explore patient stories

Work with your doctor—a 14-day dosing schedule may be possible

ALPROLIX prophy offers you the possibility of extended dosing options—of up to 14 days or beyond—that may ease the burden of treatment with fewer infusions.
It’s freedom and flexibility that may make a difference in your active life.

54% extended dosing icon

More than half of the patients in the B-LONG clinical trials who started with 10-day dosing (at 100 IU/kg) extended dosing to 14 days or longer.

54% of people in the individualized prophy arm of the B-LONG study extended to ≥14-day dosing. The overall median dosing interval on study was 12.5 days.

4.3 years calendar icon

4.3 years was the median amount of time spent on ≥14-day dosing schedule, according to a later analysis.*

Extended dosing options: ≥14-day dosing interval calendar icon

  • People started extending their dosing schedule at a weekly median of 62.5 IU/kg (59-71.3); most were on individualized prophy beforehand and were well controlled before extending their time between doses
  • Overall median dosing schedule in the B-LONG trial was 12.5 days (10.4-13.4)
  • Additional people were able to extend their dosing schedule during the B-YOND extension trial
  • People in the Kids B-LONG trial were not included in this later analysis

*Data are reported from a later analysis of 23 adult and adolescent people (aged ≥12 years) who received ALPROLIX prophylaxis with a dosing schedule of ≥14 days at any time during B-LONG or B-YOND.

View a step-by-step video and see how ALPROLIX is prepared and infused

Find your CoRe Manager and connect today
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education and support to people living with hemophilia and their families, including treatment options and lifestyle tips. Use our CoRe Locator to find the CoRe Manager in your area.
Find my CoRe

Important Safety Information and Indication

Indication

ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.

Important Safety Information

Do not use ALPROLIX if you are allergic to ALPROLIX or any of the other ingredients in ALPROLIX.

Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies and all your medical conditions, including if you are pregnant or planning to become pregnant, are breastfeeding, or have been told you have inhibitors (antibodies) to Factor IX.

Common side effects of ALPROLIX include headache, abnormal sensation in the mouth, and pain in your side with blood in your urine, which may be a sign of clot formation in the urinary collecting system.

Allergic reactions may occur with ALPROLIX. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: hives, chest tightness, wheezing, difficulty breathing, or swelling of the face.

Redness to the skin at the injection site may also occur.

ALPROLIX may increase the risk of formation of abnormal blood clots in your body, especially if you have risk factors for developing blood clots. Call your healthcare provider or seek emergency care if you have symptoms of a possible abnormal blood clot, which may include: chest pain, difficulty breathing, unexpected swelling of an arm or leg with or without pain or tenderness.

Your body can also make antibodies called "inhibitors" against ALPROLIX, which may stop ALPROLIX from working properly.

These are not all of the possible side effects of ALPROLIX. Talk to your healthcare provider right away about any side effect that bothers you or does not go away, or if bleeding is not controlled using ALPROLIX.
© 2024 Sanofi. All rights reserved. ALPROLIX and Sanofi are registered trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners. MAT-US-2021804-V8.0-10/2024 Last updated: October 2024